5 x 10 mL injection vials of gadoxetate disodium?is a hepatospecific paramagnetic gadolinium-based contrast agent, used exclusively in MRI liver imaging. Its chief use is in hepatic lesion characterization, i.e. assessing focal liver lesions identified on other imaging studies.
BAYER EOVIST 10ML is a specialized solution for injection containing gadoxetate disodium, manufactured by Bayer HealthCare Pharmaceuticals Inc. It is a gadolinium-based contrast agent (GBCA) specifically designed for MRI imaging studies of the liver.
As a paramagnetic agent, it increases radiofrequency signal intensity, making it easier to detect focal liver lesions and other abnormalities in liver tissues. It’s widely used for precise evaluation following non-contrast MRI results.
EOVIST is vital in evaluating focal liver disease, including hepatic hemangiomas and nodular hyperplasia. It is commonly used in clinical studies to assess lesion characteristics during both pre-contrast and dynamic phase imaging.
A single intravenous injection is typically used for adults, with the maximum dose based on body weight. The product is a yellow solution for injection containing gadoxetate disodium, and should be checked for particulate matter before use.
This aqueous solution provides enhanced hepatocyte phase images and improves gradient-echo images for accurate diagnosis. It’s highly effective in differentiating between benign and malignant liver conditions, even when extracellular space distortion is present.
Its unique retention characteristics in liver tissues enable detection of small lesions and abnormal vascularity, especially useful in end-stage liver disease or glycogen storage disease type.
As with all types of contrast media, adverse reactions may occur, particularly in patients with impaired kidney function or a history of allergic responses. Patients may experience adverse effects like chest pain, cutaneous manifestations, or allergic reactions after administration of gadolinium. Adverse reaction rates are usually low but vary by patient history.
Use with caution in patients with severe kidney disease, moderate kidney disease, or mild kidney disease, as impaired elimination may increase the risk of Systemic Fibrosis or adverse reactions.
The elimination half-life of gadoxetate disodium is critical in patients with impaired renal function. It typically takes hours to days for the body to clear the contrast through renal excretion and biliary excretion.
Clinical pharmacology studies show that retention in organs in patients with renal failure can lead to debilitating fibrosis. Therefore, careful dosage and administration is crucial.
Patients should be informed using the FDA-approved patient labeling and advised about potential clinical consequences of gadolinium retention, including possible effects on joints with trouble moving or fetal tissues.
Gadoxetate disodium has shown strong performance in cohort studies, even in complex cases like malignant breast disease, coronary artery disease, or quadrant pain in women with a history of breast cancer.
It supports a range of advanced sequences, including:
Radiologists also benefit from comparing pre-contrast images and reconstruction images to confirm lesion types, such as solitary hyperdense lesions or flash-filling hemangiomas.
BAYER EOVIST 10ML is more than just a contrast agent—it’s a clinical tool trusted by radiologists across the U.S. Manufactured by Bayer HealthCare Pharmaceuticals, it represents the gold standard in GBCA MRI liver imaging.
At Spectrum Medical Imaging Co., we understand your need for precision, reliability, and support. Our expert team ensures that health professionals receive not only the best products, but also medical advice, technical details, and fast delivery.
Contact Spectrum today to learn more about our supply of EOVIST and other diagnostic imaging solutions. Take the next step in improving patient outcomes with trusted, FDA-approved medical products.
